信迪利单抗联合XP化疗方案治疗胃癌患者的疗效及安全性分析  

Efficacy and safety of sindilizumab combined with XP chemotherapy in the treatment of gastric cancer patients

作　　者：朱智云 孙海峰 杨榕 ZHU Zhi-yun;SUN Hai-feng;YANG Rong(Department of Pharmacy,Zhangye People's Hospital Affiliated to Hexi University,Zhangye 734000,China.)

机构地区：[1]河西学院附属张掖人民医院药学部,甘肃张掖734000 [2]河西学院附属张掖人民医院心胸肿瘤外科,甘肃张掖734000 [3]河西学院附属张掖人民医院检验科,甘肃张掖734000

出　　处：《医师在线》2024年第7期19-21,共3页Journal of Doctors Online

摘　　要：目的探讨信迪利单抗联合XP化疗方案治疗胃癌的疗效及安全性。方法选取2020年9月~2023年3月河西学院附属张掖人民医院收治的86例胃癌患者作为研究对象,按照随机数字表法将其分为对照组和研究组,各43例。对照组采用XP化疗方案(卡培他滨+顺铂)治疗,研究组在对照组的基础上联合信迪利单抗治疗。对比两组患者的临床疗效、肿瘤标志物水平和不良反应。结果研究组的客观缓解率(ORR)和疾病控制率(DCR)高于对照组(P<0.05)。治疗前,两组癌胚抗原(CEA)、糖类抗原-125(CA125)、糖类抗原-199(CA199)水平对比无显著差异(P>0.05);治疗后,两组CEA、CA199、CA125水平均呈下降趋势,研究组CEA、CA199、CA125水平较对照组更低(P<0.05)。对照组和研究组不良反应发生率分别为58.14%、53.49%,差异无统计学意义(P>0.05)。结论信迪利单抗联合XP方案治疗胃癌的临床效果好,能改善患者肿瘤标志物水平。Objective To evaluate the efficacy and safety of sindilizumab combined with XP chemotherapy in the treatment of gastric cancer.Methods A total of 86 patients with gastric cancer admitted to Zhangye People's Hospital Affiliated to Hexi University from September 2020 to March 2023 were selected as the research objects.They were divided into study group and control group with 43 cases in each group according to random number table method.The control group received XP chemotherapy(Capecitabine+Cisplatin),and the study group received sintilizumab on the basis of the control group.The clinical efficacy,tumor marker levels and adverse reactions were compared between the two groups.Results The objective response rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group(P<0.05).Before treatment,there were no significant differences in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)between the two groups(P>0.05).After treatment,the levels of CEA,CA199 and CA125 in the two groups showed a downward trend,and the levels of CEA,CA199 and CA125 in the study group were lower than those of the control group(P<0.05).The incidence of adverse reactions was 58.14%in the control group and 53.49%in the study group,with no statistical significance(P>0.05).Conclusion Sindilizumab combined with XP chemotherapy is effective in the treatment of gastric cancer,which can improve the tumor markers level.

关 键 词：胃癌 信迪利单抗 XP方案 临床疗效 

分 类 号：R73[医药卫生—肿瘤]